[1] 吴悦,唐业忠,方光战.帕金森病步态障碍发生机制及动物模型[J].科学通报,2023,68(23): 3043-3051.
[2] 刘书一,王正波. 非人灵长类帕金森动物模型中的行为学评估[J].中国比较医学杂志, 2023,33(11):96-103.
[3] BIERI G, BRAHIC M, BOUSSET L, et al. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathol. 2019;137(6):961-980.
[4] LIU T, GUO D, WEI J. The pathogenesis of Parkinson’s disease and crosstalk with other diseases. Biocell. 2024;48(8):1155-1179.
[5] TREVISAN L, GAUDIO A, MONFRINI E, et al. Genetics in Parkinson’s disease,state-of-the-art and future perspectives. Br Med Bull. 2024; 149(1):60-71.
[6] FOLTYNIE T, BRUNO V, FOX S, et al. Medical, surgical, and physical treatments for Parkinson’s disease. Lancet. 2024;403(10423):305-324.
[7] WANG Q, LIU Y, ZHOU J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl. Transl Neurodegener. 2015;4:19.
[8] XIAO B, ZHOU Z, CHAO Y, et al. Pathogenesis of Parkinson’s Disease. Neurol Clin. 2025;43(2): 185-207.
[9] 王美华,干敏,吴海琴,等.不同训练负荷太极拳运动对早中期帕金森病患者康复疗效[J].生物化学与生物物理进展,2023,50(10):2487-2495.
[10] LAL R, SINGH A, WATTS S, et al. Experimental models of Parkinson’s disease: Challenges and Opportunities. Eur J Pharmacol. 2024;980:176819.
[11] SUBHAN I, SIDDIQUE YH. Modeling of Parkinson’s Disease in Different Models. CNS Neurol Disord Drug Targets. 2025;24(2):102-114.
[12] HE S, RU Q, CHEN L, et al. Advances in animal models of Parkinson’s disease. Brain Res Bull. 2024;215:111024.
[13] 杨东明,杨利峰,赵德明,等.帕金森病动物模型的研究进展[J].中国实验动物学报,2020, 28(3):397-404.
[14] 王子瑜,王晓慧.帕金森病动物模型研究进展[J].中国神经精神疾病杂志,2025,51(3):186-192.
[15] 陈悦,陈超美,刘则渊,等.CiteSpace知识图谱的方法论功能[J].科学学研究,2015, 33(2):242-253.
[16] KONG Q, FAN C, ZHANG Y, et al. Rare disease publishing trends worldwide and in China: ACiteSpace-based bibliometric study. Intractable Rare Dis Res. 2025;14(1):1-13.
[17] 陈忻,张楠,赵晖,等.鱼藤酮致帕金森病大鼠行为学与黑质病理损伤的关系[J].中国神经精神疾病杂志,2008,34(4):232-234.
[18] POEWE W, SEPPI K, TANNER CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
[19] BETARBET R, SHERER TB, MACKENZIE G, et al.Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3(12):1301-1306.
[20] 曹依群,周晓平,胡小吾,等.脑深部电刺激猴帕金森病模型的建立[J].立体定向和功能性神经外科杂志,2005,18(5):30-33.
[21] 徐美玲,张帆,张瑜,等.Prnp-SNCA-A53T帕金森病转基因小鼠肠道菌群差异[J].中国实验动物学报,2021,29(3):284-292.
[22] 孔健达,解瑛傲,马雯,等.帕金森病相关线粒体功能障碍及运动对其潜在的改善作用[J].中国组织工程研究,2024,28(27):4413-4420.
[23] LEHMANN S, COSTA AC, CELARDO I, et al. Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson’s disease. Cell Death Dis. 2016;7(3):e2166.
[24] BURBULLA LF, SONG P, MAZZULLI JR, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science. 2017;357(6357):1255.
[25] 肖琪,樊慧杰,李艳荣,等.PARK2介导的帕金森病中帕金蛋白对α-突触核蛋白的作用[J].中国老年学杂志,2024,44(4):999-1005.
[26] YANG K, LV Z, ZHAO W, et al.The potential of natural products to inhibit abnormal aggregation of α-Synuclein in the treatment of Parkinson’s disease. Front Pharmacol. 2024;15:1468850.
[27] ZHANG J, ZHOU D, ZHANG Z, et al. miR-let-7a suppresses α-Synuclein-induced microglia inflammation through targeting STAT3 in Parkinson’s disease. Biochem Biophys Res Commun. 2019;519(4):740-746.
[28] 李少创,韩诚,秦亚莉,等.阿尔茨海默病实验动物模型评述[J].中国实验动物学报,2022, 30(1):131-145.
[29] 赵晓阳,王小玲,梁文娜,等.丁苯酞对帕金森小鼠模型细胞凋亡和氧化应激的影响[J].中国临床药理学杂志,2021,37(16):2209-2212.
[30] WANG G, ZHUANG W, ZHOU Y, et al. 17β-estradiol alleviated ferroptotic neuroinflammation by suppressing ATF4 in mouse model of Parkinson’s disease. Cell Death Discov. 2024;10(1):507.
[31] ZHOU Y, LU M, DU R, et al. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol Neurodegener. 2016;11:28.
[32] CHENG W, FANG K, OUYANG X, et al. Vagus nerve stimulation with a small total charge transfer improves motor behavior and reduces neuroinflammation in a mouse model of Parkinson’s disease. Neurochem Int. 2024;180: 105871.
[33] JIANG Z, WANG X, ZHANG H, et al. Ketogenic diet protects MPTP-induced mouse model of Parkinson’s disease via altering gut microbiota and metabolites. MedComm (2020). 2023;4(3):e268.
[34] LEE YZ, CHENG S, CHANG M, et al. Neuroprotective Effects of Lactobacillus plantarum PS128 in a Mouse Model of Parkinson’s Disease: The Role of Gut Microbiota and MicroRNAs. Int J Mol Sci. 2023;24(7):6794.
[35] BHATTARAI Y, SI J, PU M, et al. Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson’s disease. Gut Microbes. 2021;13(1):1866974.
[36] 谌盈帆,郝斐然,汤响林,等.基于核受体辅激活因子4介导的铁自噬探讨补肾活血颗粒对帕金森病模型小鼠脑黑质神经元铁死亡的影响[J].中华中医药杂志,2024,39(2):926-931.
[37] 高达,黎庆连,王启章,等.艾灸调控SNX5对帕金森病模型小鼠神经元铁死亡的影响[J].针刺研究,2024,49(7):736-742.
[38] 卢冬磊,张文玉,谭思洁,等.运动调控铁死亡改善帕金森病的潜在机制[J].生物化学与生物物理进展,2024,51(11):2880-2896.
[39] KOO JH, CHO JY. Treadmill Exercise Attenuates α-Synuclein Levels by Promoting Mitochondrial Function and Autophagy Possibly via SIRT1 in the Chronic MPTP/P-Induced Mouse Model of Parkinson’s Diseasee. Neurotox Res. 2017; 32(3):473-486.
[40] 吴成举,英锡相,陈靖,等.针刺疗法对帕金森病大鼠黑质神经元凋亡蛋白bcl-2、bax的影响[J].陕西中医,2020,41(1):8-11+133.
[41] 王照钦,钟蕊,高崚,等.针刺对帕金森病模型小鼠肠道菌群多样性的调节作用[J].中华中医药杂志,2020,35(5):2265-2270.
[42] 刘艳阳,郭雅碧,翟宏宇,等.电针调节NLRP3/Caspase-1通路对帕金森病大鼠多巴胺能神经元焦亡的影响[J].针刺研究,2022,47(11):983-992.
[43] 王飞,李亚楠,张小蕾,等.电针调节PI3K/AKT/mTOR信号通路激活帕金森大鼠脑组织自噬改善行为学反应机制[J].中国临床解剖学杂志, 2023,41(6):709-715.
[44] 刘麒麟,邱百怡,靳晶,等.基于cGAS-STING信号通路探究针刺对帕金森病认知障碍大鼠神经炎性反应的影响[J].针刺研究,2025,50(2): 159-166.
[45] 郭雨驰,季昭臣,黎敬波.基于复杂网络分析中医药治疗帕金森病用药规律[J].中医杂志, 2018,59(24):2142-2147.
[46] 王雨,孟芊,邰国香,等.天麻素对帕金森氏症模型大鼠mTOR/HIF-1α通路、糖酵解代谢的影响[J].时珍国医国药,2023,34(12):2852-2856.
[47] 郇鹏飞,何竹青,王利,等.病证结合帕金森病小鼠模型的构建及中医证候属性研究[J].上海中医药大学学报,2022,36(2):36-42.
[48] CHEN Z, ZHAO G. First-in-human transplantation of autologous induced neural stem cell-derived dopaminergic precursors to treat Parkinson’s disease. Sci Bull (Beijing). 2023;68(22):2700-2703.
[49] DU X. Modulation of the PI3K/AKT pathway by using Traditional Chinese Medicines in treating Parkinson’s disease: A review of animal model studies. Bol Latinoam Caribe Plant Med Aromat. 2025; 23(2):172-185.
[50] LI M, WANG H, BAI Y, et al. Pharmacodynamical research of extracts and compounds in traditional Chinese medicines for Parkinson’s disease. Fitoterapia. 2024;177:106086.
[51] WU J, LI CS, HUANG WY, et al. Gut microbiota promote the propagation of pathologic α-syn from gut to brain in a gut-originated mouse model of Parkinson’s disease. Brain Behav Immun. 2025;128:152-169.
[52] FENG M, ZOU Z, SHOU P, et al. Gut microbiota and Parkinson’s disease: potential links and the role of fecal microbiota transplantation. Front Aging Neurosci. 2024;16:1479343.
[53] YAO Z, JIAO Q, DU X, et al.Ferroptosis in Parkinson’s disease -- The iron-related degenerative disease. Ageing Res Rev. 2024;101:102477.
[54] CLARK BJ, LELOS MJ, LORING JF. Advancing Parkinson’s disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells. Stem Cells. 2024;42(9):781-790.
[55] 张逸悦,王峰.人工智能与PET/MR在帕金森病诊断中的应用[J].南京医科大学学报(自然科学版),2024,44(6):876-881.
[56] 任虹宇,马俊,何森,等.丘脑底核脑深部电刺激术治疗帕金森病患者的疗效及术后认知功能分析[J].中国实用神经疾病杂志,2024,27(4): 448-452.
[57] 罗文豪.机器人辅助丘脑底核脑深部电刺激治疗帕金森病的疗效分析[D].南昌:南昌大学, 2024.
[58] 王子豪,夏欢,冯婷婷,等.基于生物信息学及机器学习算法筛选诊断帕金森病的枢纽基因[J].神经疾病与精神卫生,2023,23(12):837-847.
[59] EGHLIDOS Z, RAHIMIAN Z, VADIEE G, et al. Effects of subthalamic deep brainstimulation on non-motor symptoms of Parkinson’s disease: A meta-analysis. Acta Neurol Scand. 2022;146(2):115-125.
[60] 徐如祥.脑芯片-脑机接口治疗技术进展[J].中华脑科疾病与康复杂志(电子版),2020, 10(6):383-384.
[61] 科技部.《脑机接口研究伦理指引》和《人-非人动物嵌合体研究伦理指引》发布[EB/OL].(2024-02-02)[2024-03-22] .https://www.most.gov.cn/kjbgz/202402/t20240202_189582.html.
|